Search Results - "Stigt, J"

Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin–gemcitabine or carboplatin–paclitaxel: NVALT-3 a phase III study by Biesma, B., Wymenga, A.N.M., Vincent, A., Dalesio, O., Smit, H.J.M., Stigt, J.A., Smit, E.F., van Felius, C.L., van Putten, J.W.G., Slaets, J.P.J., Groen, H.J.M.

“…Elderly patients with advanced non-small-cell lung cancer (NSCLC) may derive similar benefit from platinum-based chemotherapy as younger patients. Quality of…”
Get full text

Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry by Smit, H.J.M., Aerts, J., van den Heuvel, M., Hiltermann, T.J.N., Bahce, I., Smit, E.F., Dingemans, A-M.C., Hendriks, L.E., Stigt, J.A., Schramel, F.M.N.H., van Tinteren, H., Groen, H.J.M.

“…•Introduction of immunotherapy did not change quality of care between hospitals.•Patients underrepresented in trials received immunotherapy in routine…”
Get full text

A Randomized Controlled Trial comparing Indwelling Pleural Catheters with Talc Pleurodesis (NVALT-14) by Boshuizen, R.C, vd Noort, V, Burgers, J.A, Herder, G.J.M, Hashemi, S.M.S, Hiltermann, T.J.N, Kunst, P.W, Stigt, J.A, van den Heuvel, M.M

“…Highlights • Indwelling pleural catheter and talc pleurodesis are both effective treatments for recurrent malignant pleural effusion. • No difference was…”
Get full text

Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study by Witlox, W.J.A., Ramaekers, B.L.T., Joore, M.A., Dingemans, A.-M.C., Praag, J., Belderbos, J., Tissing-Tan, C., Herder, G., Haitjema, T., Ubbels, J.F., Lagerwaard, J., El Sharouni, S.Y., Stigt, J.A., Smit, E.F., van Tinteren, H., van der Noort, V., Groen, H.J.M., De Ruysscher, D.K.M.

“…•Scores of the HRQoL metrics were not different between PCI and observation.•HRQoL was lower in patients with neurocognitive symptoms and BM.•The utility score…”
Get full text

A randomized phase II study comparing paclitaxel–carboplatin–bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170) by Dingemans, A.-M. C., Groen, H.J.M., Herder, G.J.M., Stigt, J.A., Smit, E.F., Bahce, I., Burgers, J.A., van den Borne, B.E.E.M., Biesma, B., Vincent, A., van der Noort, V., Aerts, J.G.

“…Nitroglycerin (NTG) increases tumor blood flow and oxygenation by inhibiting hypoxia-inducible-factor (HIF)-1. A randomized phase II study has shown improved…”
Get full text

Identifying Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Most Likely to Benefit From Intensive Radiation Therapy by Slotman, B.J, Faivre-Finn, C, van Tinteren, H, Keijser, A, Praag, J.O, Knegjens, J, Hatton, M, van Dam, I, van der Leest, A, Reymen, B, Stigt, J, Haslett, K, Tripathi, D, Smit, E, Senan, S

Get full text

Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype by Hermans, B C M, Derks, J L, Groen, H J M, Stigt, J A, van Suylen, R J, Hillen, L M, van den Broek, E C, Speel, E J M, Dingemans, A-M C

“…Introduction Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67…”
Get full text

A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin–docetaxel, plus radical concurrent chemoradiotherapy with cisplatin–docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer by Senan, S., Cardenal, F., Vansteenkiste, J., Stigt, J., Akyol, F., De Neve, W., Bakker, J., Dupont, J.-M., Scagliotti, G.V., Ricardi, U., van Meerbeeck, J.P.

“…In stage III non-small-cell lung cancer (NSCLC), the role of systemic chemotherapy preceding or following concurrent chemo-radiotherapy (CT-RT) is unclear. We…”
Get full text

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment by WACHTERS, F. M, GROEN, H. J. M, BIESMA, B, SCHRAMEL, F. M. N. H, POSTMUS, P. E, STIGT, J. A, SMIT, E. F

“…Response rate and toxicity of second-line therapy with docetaxel (75 mg m(-2)) or docetaxel, irinotecan, and lenogastrim (60 mg m(-2), 200 mg m(-2), and 150…”
Get full text

Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy by van Elsas, Marit J, Labrie, Camilla, Etzerodt, Anders, Charoentong, Pornpimol, van Stigt Thans, Jordi J C, Van Hall, Thorbald, van der Burg, Sjoerd H

“…BackgroundPrimary and secondary resistance is a major hurdle in cancer immunotherapy. Therefore, a better understanding of the underlying mechanisms involved…”
Get full text

International perspective of injection laryngoplasty for laryngeal cleft – A survey study by van Stigt, Marit J.B., Coenraad, Saskia, Stegeman, Inge, Stokroos, Robert J., Tytgat, Stefaan H.A.J., Lindeboom, Maud Y.A., Bittermann, Arnold J.N.

“…Laryngeal Cleft (LC) is an anatomical defect that can cause swallowing difficulties and subsequent recurrent respiratory symptoms. LC can be treated surgically…”
Get full text

Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: an EORTC phase II study (EORTC 08958) by O'Brien, M.E.R, Splinter, T, Smit, E.F, Biesma, B, Krzakowski, M, Tjan-Heijnen, V.C.G, Van Bochove, A, Stigt, J, Smid-Geirnaerdt, M.J.A, Debruyne, C, Legrand, C, Giaccone, G

“…The aim of this study was to document the activity and toxicity of paclitaxel (Taxol)/carboplatin when used as induction chemotherapy in patients with stage…”
Get full text

Indication and efficacy of injection laryngoplasty for laryngeal clefts - A retrospective cohort study by van Stigt, Marit J.B., Coenraad, Saskia, Stegeman, Inge, Stokroos, Robert J., Tytgat, Stefaan H.A.J., Lindeboom, Maud Y.A., Bittermann, Arnold J.N.

“…Laryngeal cleft (LC) is an anatomical defect of the larynx, where there is a gap (or cleft) between the arytenoids. Milder types can be treated with injection…”
Get full text

Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy by Groeneveldt, Christianne, Kinderman, Priscilla, van Stigt Thans, Jordi J C, Labrie, Camilla, Griffioen, Lisa, Sluijter, Marjolein, van den Wollenberg, Diana J M, Hoeben, Rob C, den Haan, Joke M M, van der Burg, Sjoerd H, van Hall, Thorbald, van Montfoort, Nadine

“…BackgroundMany solid tumors do not respond to immunotherapy due to their immunologically cold tumor microenvironment (TME). We and others found that oncolytic…”
Get full text

Injection laryngoplasty for laryngeal cleft type I in an 8-week-old infant by van Stigt, Marit J B, van Oorschot, Hanneke D, Bittermann, Arnold J N

“…A laryngeal cleft is a rare anatomical deformity which is increasingly treated with injection laryngoplasty. Since diagnosis of laryngeal cleft type I is often…”
Get full text

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study by de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne-Marie C., van der Veldt, Astrid A.M., van Loenhout, C.J., van der Leest, C.H., Becker-Commissaris, A., Borgers, J.S.W., Terhegggen, F., van den Borne, B.E.E.M., van Warmerdam, L.J.C., van Leeuwen, L., van der Meer, F.S., Tiemessen, M.A., van Diepen, D.M., Klaver, Y., Hamberg, A.P., Libourel, E.J., Strobbe, L., Cloos, M., Geraedts, E.J., Drooger, J.C., Heller, R., de Groot, J.W.B., Stigt, J.A., Nuij, V.J.A.A., Pitz, C.C.M., Slingerland, M., Borm, F.J., Haberkorn, B.C.M., Westeinde, S.C. van 't, Aarts, M.J.B., van Putten, J.W.G., Youssef, M., Cirkel, G.A., Herder, G.J.M., van Rooijen, C.R., Citgez, E., Barlo, N.P., Scholtes, B.M.J., Koornstra, R.H.T., Claessens, N.J.M., Faber, L.M., Rikers, C.H., van de Wetering, R.A.W., Veurink, G.L., Bouter, B.W., Houtenbos, I., Bard, M.P.L., Herbschleb, K.H., Kastelijn, E.A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T.J.N., Schuurbiers-Siebers, O.C.J., Suijkerbuijk, K.P.M., van Lindert, A.S.R., van de Wouw, A.J., van den Boogaart, V.E.M., Bakker, S.D., Looysen, E., Peerdeman, A.L., de Jong, W.K., Siemerink, E.J.M., Staal, A.J., Franken, B., van Geffen, W.H., Bootsma, G.P.

“…Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse…”
Get full text

Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial by Billingy, Nicole E, Tromp, Vashti N M F, Aaronson, Neil K, Hoek, Rianne J A, Bogaard, Harm Jan, Onwuteaka-Philipsen, Bregje D, van de Poll-Franse, Lonneke, Hugtenburg, Jacqueline G, Belderbos, José, Becker-Commissaris, Annemarie, van den Hurk, Corina J G, Walraven, Iris

“…Previous studies using patient-reported outcomes measures (PROMs) to monitor symptoms during and after (lung) cancer treatment used alerts that were sent to…”
Get full text

127P Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)? by Hendriks, L., Keek, S.A., Chatterjee, A., Belderbos, J., Bootsma, G., van den Borne, B., Dingemans, A-M.C., Gietema, H., Groen, H.J.M., Herder, G., Pitz, C., Praag, J., De Ruysscher, D., Schoenmaekers, J., Smit, H.J.M., Stigt, J., Westenend, M., Zeng, H., Woodruff, H., Lambin, P.

Get full text

Pulmonary function in Parkinson's disease by Hovestadt, A, Bogaard, J M, Meerwaldt, J D, van der Meché, F G, Stigt, J

“…Pulmonary function was investigated in 31 consecutive patients with relatively severe Parkinson's disease. Clinical disability was assessed by Hoehn and Yahr…”
Get full text

Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19) by Burgers, S.A., de Gooijer, C., Cornelissen, R., Aerts, J.G., Biesma, B., Heemst, R.V., Youssef-El Soud, M., Groen, H.J.M., Staal-van den Brekel, A.J., Bootsma, G., Schijen, J H E M, Baas, P., Giovannetti, E., de Vries, J.F., Hogenboom, F.A., de Wit, D.C.M., Mahn- Schaefers, M.C.W., Lalezari, F., van de Noort, V., Stigt, J.

Get full text